Conneqt Health Limited · ASX:CQT
Conneqt Health — CardieX — Corporate Update (May 2021)
37 slides from Conneqt Health's corporate update, May 2021
Slide 1: Corporate Update
May 2021 Corporate Update
Slide 2: CardieX is a health-technology company focused on vascular and arterial health
CardieX is a health-technology company that focuses on vascular and arterial health. Our two operating divisions develop and market medical and consumer devices & digital solutions for the world’s largest health disorders - all based on our patented, FDA-cleared SphygmoCor® central blood pressure te
Slide 3: Key Company Highlights
Devices and digital solutions for the world’s largest vascular health disorders - including hypertension, cardiovascular disease, cognitive health, diabetic retinopathy, renal disease. Our SphygmoCor® technology non-invasively measures the vascular health of key organs (heart, brain, kidneys) and he
Slide 4: Our Core Technology
Health Parameters Our Core Technology Our patented SphygmoCor® technology measures “central blood pressure" and “arterial waveforms” providing advanced medical and consumer health parameters not available from traditional blood pressure devices. Arterial Age (ArtyAge™) Blood Pressure (SYS/DIA) Arter
Slide 5: Benefits of Central Blood Pressure Measurement (cBP)
Benefits of Central Blood Pressure Measurement (cBP) 1 4 More precise and accurate determination of More precise targeting of prescription drugs - CardieX hypertension and risk of vascular related diseases such analysis estimates approx $USD1.65B in annual cost as Alzheimer's, stroke, kidney, renal,
Slide 6: Total Addressable Population Size
Total Addressable Population Size Our technology solutions have significant medical Diabetes - Management of central systolic blood pressure and consumer applications across the worlds largest (CSBP) essential for identifying risk of diabetic retinopathy. health disorders. 578m global diabetics by 2
Slide 7: Total Addressable Market Size
$550B Total Addressable Market Size Annual Addressable Market Opportunity Global Blood Pressure Monitoring - Market Value 2017 2025 1.04 B 2.5 B USD USD (Fortune Business Insights) (Fortune Business Insights) Health Wearables Market - Market Value 2020 2027 37.1 B 104.4 B USD USD (Grand View Researc
Slide 8: Our Operating Companies
Our Operating Companies Specialist Medical Devices and Data Solutions (B2B) Our two operating companies leverage our FDA-cleared and patented SphygmoCor® technology for specialized health market solutions - with separate go-to-market, brand, and sales strategies. Home, consumer, and primary care dev
Slide 9: ATCOR Overview
ATCOR Specialist Medical Devices and Data Solutions (B2B) Medical Devices SaaS Solutions IP Licensing OVERVIEW The only devices cleared by the FDA to measure central arterial waveform pressure in adults. Portfolio of company owned & jointly developed products: • XCEL SphygmoCor®- “gold standard” for
Slide 10: ATCOR Partners & Customers
ATCOR Partners & Customers We sell, lease, license, and provide data management software services to*: Research and pharmaceutical companies for clinical trial services related to hypertension, cardiovascular disease, diabetes, and renal disease. Specialist physician practices - Cardiology, Nephrolo
Slide 11: ATCOR FY/2022 Growth Plan and Path to Profitability
ATCOR FY/2022 Growth Plan and Path to Profitability • New leadership under Chris Dax (ex-Masimo VP of Sales). • Major operating and sales team expansion in clinical trial services (Michael Schulz - (Welch Allyn/Mortara) + Bob Hayes). • Expanded sales and marketing focus targeting VA’s, IDN’s, CRO’s
Slide 12: 12
12
Slide 13: CONNEQT Overview
CONNEQT Home, consumer, and primary care devices and digital solutions. Home health Wearables Companion apps OVERVIEW • Targeting mass market consumer health products and primary care (GP) devices. • Direct to consumer (D2C) and direct to business (B2B) online sales focus. • Five (5) new products in
Slide 14: Spotlight: CONNEQT PULSE
CONNEQT PULSE (Q2/FY22) World’s first consumer dual blood pressure monitor (BPM). SPOTLIGHT • Customizable UI/device screens based on personal user health requirements - world first BPM UI/UX. • Multiple trademarked and patented health parameters previously only available to specialist physicians, r
Slide 15: Spotlight: CONNEQT BAND
CONNEQT BAND (Q4/FY22) Significant global market opportunity in wearable health devices driven by: SPOTLIGHT • 1.3B global hypertensives + multiple other vascular health sectors. • Growth in global wearable devices to $USD104.4B by 2027. • Medicare “remote monitoring codes” (average $440 per physici
Slide 16: CONNEQT BAND Overview
CONNEQT BAND • Targeted at health conscious consumers with underlying vascular health conditions (heart, brain, renal, arterial). OVERVIEW • Incorporates CardieX’s patent pending PPG sensor algorithms for advanced arterial health monitoring (May/2020). • First dual PPG sensor wearable incorporating
Slide 17: CONNEQT BAND Wearable Market Positioning
CONNEQT BAND Wearable Market Positioning Health Tech LifeStyle 17
Slide 18: CONNEQT Sample Go-To-Market & Launch Partnerships
A Healthy You. In a Heartbeat. CONNEQT Sample Go-To-Market & Launch Partnerships* World Heart Day #24BEATS World Hypertension Day Eat Smart Month #HEALTHWALK #EATSMART *Illustrative purposes only 18
Slide 19: CONNEQT Sample Marketing Campaigns
CONNEQT Sample Marketing Campaigns* *Illustrative purposes only 19
Slide 20: Spotlight: CONNEQT Companion App
CONNEQT COMPANION APP Health Parameters and Analytics for PULSE & CONNEQT BAND SPOTLIGHT CONNEQT Basic Features • Health parameter dashboard with historical view and trends. • Arty heart health AI coaching and recommendations. • Heart health personal and group challenges. • Data sharing with friends
Slide 21: Spotlight: CONNEQT Companion App (cont.)
CONNEQT COMPANION APP for PULSE & CONNEQT BAND (cont.) SPOTLIGHT Health Coaching, Personalized Health Cards Recommendations & Insights 21
Slide 22: CardieX Capital Structure - Overview
CardieX Capital Structure - Overview Market Cap (@ $0.07): $66m CardieX Share Price: April 2020 to April 23, 2021 Cash (31/03/2021): $4.8m Shares, Options, & Fully Diluted Capital (MM) ASX Listed Shares 925 ASX Listed Options (5c strike, expiry 11/21, 127 raising $6.37m) Total ASX Listed Capital 1,0
Slide 23: Revenue
Historical & Current (2021) Revenue Run Rate. Revenue (2018 - 2021) 6,000,000 Notes: 5,250,000 • Actual Revenue for FY’s: 2018, 2019, & 2020. • Annualised Revenue based Revenue on Year to 31 March 2021. 4,500,000 • YTD growth – 34% (constant currency), >20% (actual currency). 3,750,000 3,000,000 201
Slide 24: Revenue Contributions 2021-2024
Revenue Contributions 2021-2024 FY21 Business Unit FY24 Revenue Contribution Revenue Contribution ATCOR Medical Technology Licensing ATCOR Medical Technology Licensing New Device SaaS and Subscription 24
Slide 25: Appendices
Appendices Board of Directors Key Management Global Presence CONNEQT PULSE - Competitive & Market Positioning CONNEQT PULSE - Development & Launch Schedule CONNEQT BAND - Competitive & Market Positioning CONNEQT BAND - Development & Launch Schedule CardieX Strategic Investments References - Total Ad
Slide 26: Board of Directors
Board of Directors Executive Chairman Non-Executive Executive Director, CEO & Co-Founder and Co-Founder Director Chief Financial Officer Craig R. Cooper Niall Cairns R. King Nelson Jarrod White BEc, LLB (Hons) BEc, ACA, FAICD BA, MBA CA, CTA, BCom(Law) UTS Founding Partner - Softbank Capital Managin
Slide 27: Key Management
Key Management Chris Dax Mark Gorelick Steven Keston President of ATCOR Chief Product Officer Chief Medical Officer Masimo Traction Health SKC Life Sciences ISTA Pharmaceuticals PAI Health Uptake Medical Elan Pharmaceuticals Performance Lab Pneuma Respiratory Valeant Step Health Boehringer Ingelheim
Slide 28: Global Presence
Global Presence Turkey Chicago EMEA Sales & BD Global Sales Bangkok Software Engineering Philadelphia Vancouver Marketing & Content Executive & Product Shanghai Uruguay Orange County APAC Sales & BD App Development Executive & Corporate Sydney R&D + Finance Total Staff 41 28
Slide 29: CONNEQT PULSE Competitive & Market Positioning
CONNEQT PULSE Competitive & Market Positioning CLINICAL HEALTH PARAMETERS CONNEQT Pulse Withings Omron A&D iHealth Beurer Brachial Blood Pressure l l l l l l Central Blood Pressure l l l l l l Standard Heart Rate l l l l l l "Medical Grade" Heart Rate (TruHR) l l l l l l Arterial Stiffness Index (AS
Slide 30: CONNEQT PULSE Milestone Timeline
Milestone Timeline Device Development/Testing Clinical Validation Study Complete Q4/FY21 Hardware Testing Q4/FY21 App/Device Testing Q4/FY21 Regulatory Submissions/Approvals FDA regulatory submission (US) Q1/FY22 CE regulatory submission (EU) Q1/FY22 CONNEQT PULSE NMPA regulatory submission (China)
Slide 31: CONNEQT BAND Competitive & Market Positioning
CONNEQT BAND Competitive & Market Positioning Clinical Grade Health Parameters CONNEQT Samsung/Galaxy Omron HeartGuide Aktiia Apple BAND Watch Watch Band Watch Brachial Blood Pressure w/ calibration l l No calibration required• l l Central Blood Pressure w/ calibration l l l l l Standard Heart Rate
Slide 32: CONNEQT BAND Competitive & Market Positioning (cont.)
CONNEQT BAND Competitive & Market Positioning (cont.) CONNEQT BAND CONNEQT Samsung/Galaxy Omron HeartGuide Aktiia Apple Consumer Health Parameters BAND Watch Watch Band Watch "Medical Grade" Heart Rate (TruHR) l l l l l Continous Heart Rate l l l l l Resting Heart Rate l l l l l Heart Rate Variabili
Slide 33: CONNEQT BAND Competitive & Market Positioning (cont.)
CONNEQT BAND Competitive & Market Positioning (cont.) CONNEQT BAND CONNEQT Samsung/Galaxy Omron HeartGuide Aktiia Apple 2021/2022 Pipeline BAND Watch Watch Band Watch Fitness Impact l l l l l Body Readiness l l l l l Daily Stress and Recovery Tracking l l l l l Fitness Level Index l l l l l Daily Ac
Slide 34: CONNEQT BAND Milestone Timeline
Milestone Timeline Device Development/Testing Hardware Development/Testing Q2/FY22 Clinical Validation Study Complete Q2/FY22 Regulatory Submissions/Approvals FDA regulatory submission (US) Q2/FY22 CONNEQT BAND FDA anticipated approval (US) Q4/FY22 Launch Schedule Manufacturing & Product Launch Tria
Slide 35: CardieX Strategic Investments
CardieX Strategic Investments Blumio, Inc (www.blumio.com) Blumio creates radar based sensor units for application in acute ICU settings. CardieX and Blumio have a Collaboration Agreement in respect of the incorporation of ATCOR’s algorithms and central pressure parameters into the Blumio radar sens
Slide 36: References
References Total Addressable Market and Population Size 1. World Health Organization. https://www.who.int/health-topics/cardiovascular-diseases/ #tab=tab_1 2. Fortune Business Insights. https://www.fortunebusinessinsights.com/industry-reports/ blood-pressure-monitors-market-100059 3. Industry Status
Slide 37: Contact
Contact: Craig Cooper CEO & Co-Founder ccooper@cardiex.com Niall Cairns Executive Chairman and Co-Founder nccairns@cardiex.com Authorised by the Board of Directors of CardieX 37